Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 08/10/26
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship ImmunoglobulinsGlobeNewsWire • 07/16/26
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)Seeking Alpha • 07/03/26
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocatesGlobeNewsWire • 03/30/26
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's DiseaseGlobeNewsWire • 03/17/26
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-complianceGlobeNewsWire • 03/13/26
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' SitesGlobeNewsWire • 03/12/26
Down 10.4% in 4 Weeks, Here's Why Grifols (GRFS) Looks Ripe for a TurnaroundZacks Investment Research • 11/06/25